Andere Sprachen Alto Neuroscience, Inc.

Aktien

A401D8

US02157Q1094

ANRO

Markt geschlossen - Nyse Andere Börsenplätze 22:00:02 26.06.2024			% 5 Tage	% 1. Jan.
9,96 ^USD	+1,22 %		-10,67 %	0,00 %

20.06.	Alto Neuroscience, Inc. Startet Phase-2-Studie mit ALTO-101, einem neuartigen PDE4-Hemmer, bei kognitiven Beeinträchtigungen im Zusammenhang mit Schizophrenie	CI
21.05.	Alto Neuroscience, Inc. ernennt Michael Hanley zum Chief Operating Officer	CI

Andere Sprachen

Schalten Sie alle Nachrichten frei: Seien Sie als Erster informiert und reagieren Sie vor den Märkten!

100% kostenlose Registrierung

Alto Neuroscience, Inc.(NYSE:ANRO) added to S&P Global BMI Index	24.06.
Alto Neuroscience Initiates Phase 2 Study of ALTO-101, a Novel PDE4 Inhibitor, in Cognitive Impairment Associated with Schizophrenia	20.06.
Alto Neuroscience, Inc. Initiates Phase 2 Study of ALTO-101, Novel PDE4 Inhibitor, in Cognitive Impairment Associated with Schizophrenia	20.06.
Amit Etkin, M.D., Ph.D., Founder and CEO of Alto Neuroscience, Named an EY Entrepreneur of the Year 2024 Bay Area Award Winner	19.06.
Amit Etkin, M.D., Ph.D., Founder and CEO of Alto Neuroscience, Named an EY Entrepreneur Of The Year® 2024 Bay Area Award Winner	18.06.
Alto Neuroscience to Present at the Jefferies Global Healthcare Conference	29.05.
Alto Neuroscience Appoints Michael Hanley as Chief Operating Officer	21.05.
Alto Neuroscience, Inc. Appoints Michael Hanley as Chief Operating Officer	21.05.
Alto Neuroscience, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	14.05.
Alto Neuroscience Reports First Quarter 2024 Financial Results and Recent Business Highlights	14.05.
Alto Neuroscience Announces Data Presentations Highlighting Late-Stage Clinical Pipeline and Robust Platform at Upcoming Scientific Conferences	09.05.
Alto Neuroscience Announces Positive Phase 1 Results for ALTO-101, a Novel PDE4 Inhibitor in Development for Schizophrenia	23.04.
Alto Neuroscience, Inc. Announces Positive Phase 1 Results for ALTO-101, A Novel PDE4 Inhibitor in Development for Schizophrenia	23.04.
Alto Neuroscience Starts Phase 2 Trial of ALTO-203 in Major Depressive Disorder Patients	03.04.
Alto Neuroscience Announces Initiation of Phase 2 Study of ALTO-203 in Patients with Major Depressive Disorder	03.04.
Alto Neuroscience, Inc. Announces Initiation of Phase 2 Study of Alto-203 in Patients with Major Depressive Disorder	03.04.
Alto Neuroscience Reports Full Year 2023 Financial Results and Recent Business Highlights	21.03.
Alto Neuroscience, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	21.03.
Alto Neuroscience, Inc.(NYSE:ANRO) added to S&P TMI Index	18.03.
Alto Neuroscience Appoints Maha Radhakrishnan, M.D., to Board of Directors	11.03.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Alto Neuroscience, Inc.

Aktien

A401D8

US02157Q1094

ANRO

Andere Sprachen

Filter